# Fosun Pharma

Type: Company

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/fosun-pharma
Canonical HTML page: https://getfinancebrief.com/entity/fosun-pharma

## Timeline

- **2026-03-24**: Annual Results — Official release of 2025 financial performance data to global markets.
- **2026**: Target Horizon — Expected period for achieving the RMB 10 billion annual profit milestone.
- **2025-11-10**: Global Partnership — Strategic agreement signed for the distribution of biosimilars in emerging markets.
- **2025-08-20**: CAR-T Milestone — Fosun Kite announces expanded indications for Yi Kai Da CAR-T therapy.
- **2025-03-15**: Regional Launch — Serplulimab receives regulatory approval in additional Southeast Asian markets.
- **2025-03-10**: Strategic Reaffirmation — Management confirms RMB 10 billion profit target and shift to growth.
- **2023**: De-Risking Phase — Aggressive asset disposals and debt reduction to stabilize the balance sheet.

## Recent coverage (2 stories)

### Fosun Pharma 2025 Results Highlight Innovation Pivot and Global Expansion
2026-03-24 17:03:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Fosun Pharma reported robust 2025 financial results, driven by a record contribution from innovative drugs and successful expansion into Southeast Asian markets. The company's strategic focus on high-barrier biologics and R&D has solidified its transition from a generic-focused manufacturer to a global innovation leader.
Full story: https://getfinancebrief.com/story/fosun-pharma-2025-annual-results-analysis

### Fosun Sets RMB 10 Billion Profit Target Amid Strategic De-Risking
2026-03-10 13:13:49 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

Fosun International has reaffirmed its commitment to a RMB 10 billion annual profit target over the next three to five years, signaling a transition from risk mitigation to sustainable growth. The management's outlook emphasizes the successful navigation of cyclical volatility and the stabilization of its core business pillars.
Full story: https://getfinancebrief.com/story/fosun-international-profit-target-de-risking

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.